Detection of aberrant hypermethylated spastic paraplegia-20 as a potential biomarker and prognostic factor in gastric cancer

Medical Oncology

Volumn 31, Issue 2, 2014, Pages

  Zhang, Hao ^a   Song, Yongchun ^a   Xia, Peng ^a   Cheng, Yao ^a   Guo, Qi ^a   Diao, Dongmei ^a   Wang, Wei ^a   Wu, Xuandi ^a   Liu, Di ^a   Dang, Chengxue ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Gastric cancer; Methylation; Screening; SPG20

Indexed keywords

BIOLOGICAL MARKER; GENOMIC DNA; PEPTIDES AND PROTEINS; SPASTIC PARAPLEGIA 20 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; PROTEIN; SPG20 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DNA EXTRACTION; DNA METHYLATION ASSAY; FEMALE; GASTRECTOMY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STOMACH CANCER; ADENOCARCINOMA; CASE CONTROL STUDY; COMPARATIVE STUDY; DNA METHYLATION; DRUG EFFECT; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PROGNOSIS; STOMACH; STOMACH TUMOR; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR INVASION;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CASE-CONTROL STUDIES; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEINS; STOMACH; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84891115935     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0830-2     Document Type: Article

References (19)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137-50.
2. Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2008;38(4):259-67.
3. Lee T-L, Leung WK, Chan MW, Ng EK, Tong JH, Lo K-W, et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res. 2002;8(6):1761-6.
4. Ichikawa D, Koike H, Ikoma H, Ikoma D, Tani N, Otsuji E, et al. Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer. Anticancer Res. 2004;24(4): 2477-82.
5. Kanyama Y, Hibi K, Nakayama H, Kodera Y, Ito K, Akiyama S, et al. Detection of p16 promoter hypermethylation in serum of gastric cancer patients. Cancer Sci. 2003;94(5):418-20.
6. Takada H, Wakabayashi N, Dohi O, Yasui K, Sakakura C, Mitsufuji S, et al. Tissue factor pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant promoter hypermethylation in gastric cancer. Cancer Genet Cytogenet. 2010;197(1):16-24.
7. Bakowska JC, Jupille H, Fatheddin P, Puertollano R, Blackstone C. Troyer syndrome protein spartin is mono-ubiquitinated and functions in EGF receptor trafficking. Mol Biol Cell. 2007;18(5):1683-92.
8. Lind G, Raiborg C, Danielsen S, Rognum T, Thiis-Evensen E, Hoff G, et al. SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis. Oncogene. 2011;30(37):3967-78.
9. Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, et al. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neurooncology. 2013;15(3):370-81.
10. Zhang H, Song Y-C, Dang C-X. Detection of hypermethylated spastic paraplegia-20 in stool samples of patients with colorectal cancer. Int J Med Sci. 2013;10(3):230.
11. Sagona AP, Stenmark H. Cytokinesis and cancer. FEBS Lett. 2010;584(12):2652-61.
12. Renvoisé B, Parker RL, Yang D, Bakowska JC, Hurley JH, Blackstone C. SPG20 protein spartin is recruited to midbodies by ESCRT-III protein Ist1 and participates in cytokinesis. Mol Biol Cell. 2010;21(19):3293-303.
13. Nahm M, Lee M-J, Parkinson W, Lee M, Kim H, Kim Y-J, et al. Spartin regulates synaptic growth and neuronal survival by inhibiting BMP-mediated microtubule stabilization. Neuron. 2013;77(4):680-95.
14. You Y-J, Chen Y-P, Zheng X-X, Meltzer SJ, Zhang H. Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients. Cancer Lett. 2012;315(2):138-44.
15. Hibi K, Goto T, Shirahata A, Saito M, Kigawa G, Nemoto H, et al. Detection of TFPI2 methylation in the serum of colorectal cancer patients. Cancer Lett. 2011;311(1):96-100.
16. Tan S-H, Ida H, Lau Q-C, Goh B-C, Chieng W-S, Loh M, et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep. 2007;18(5):1225-30.
17. Yu J, Zhu T, Wang Z, Zhang H, Qian Z, Xu H, et al. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer. Clin Cancer Res. 2007;13(24):7296-304.
18. Wong IH, Zhang J, Lai PB, Lau WY, Lo YD. Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients. Clin Cancer Res. 2003;9(3):1047-52.
19. Wong TS, Kwong DL-W, Sham JS-T, Tsao SW, Wei WI, Kwong YL, et al. Promoter hypermethylation of high-in-normal 1 gene in primary nasopharyngeal carcinoma. Clin Cancer Res. 2003;9(8): 3042-6.